Prognosis
Takeda Accused of Favoring Japanese Patients for Cancer Drug
- U.S. patients faced shortages of Lupron, consultant says
- Abbvie asking judge to order Takeda to honor supply agreement
This article is for subscribers only.
Takeda Pharmaceutical Co.’s internal files show the Japanese company sought to limit shortages of the cancer drug Lupron in its home market and knew the measures would lead to shortages for American patients, said a consultant for AbbVie Inc., which sold the medication in the U.S.
The files show Takeda officials juggled Lupron shipments starting in early 2020 in a way that provided “minimal disruption” to markets in Japan and China, sales consultant John Russell testified Wednesday at a trial before Delaware Chancery Court Judge Sam Glasscock III. Abbvie sued Takeda for failing to fulfill its 2008 Lupron supply agreement.